Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Covid19
Interventions: Selenium (as Selenious Acid), Placebo; Drug · Other
Lead sponsor: CHRISTUS Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Longview, Texas

Conditions: HIV Infection
Interventions: Tenofovir Disoproxil Fumarate 300 mg daily; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 29 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions: Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more

Conditions: HIV-1 Infection
Interventions: BMS-986001, Placebo matching with BMS-986001, Efavirenz, Lamivudine, Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: Sacramento, California • Orlando, Florida • West Palm Beach, Florida + 15 more

Conditions: Adenovirus
Interventions: Brincidofovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Months to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Washinton, District of Columbia • Atlanta, Georgia + 17 more

Conditions: Malignant Female Reproductive System Neoplasm
Interventions: Infection Prophylaxis and Management; Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 19 Years and older · Female only
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Drug Safety
Interventions: MDT-637; Drug
Lead sponsor: MicroDose Therapeutx, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hepatitis C, Chronic, Opioid-use Disorder
Interventions: Sofosbuvir/Velpatasvir; Drug
Lead sponsor: Elizabeth Krans, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumonia, Aspiration Pneumonia
Interventions: Videofluoroscopic Swallowing Study, Nuclear medicine pulmonary aspiration study, TOR-BSST and 3 oz Water Swallow, Sputum Culture, MeMed BV®, Lung Ultrasound, Respiratory Function Tests; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Infectious Gastroenteritis
Interventions: FilmArray™ Gastrointestinal (GI) Panel; Device
Lead sponsor: BioFire Diagnostics, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 1,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Kansas City, Missouri • Columbus, Ohio + 2 more

Conditions: Herpes Simplex, HIV Infections
Interventions: Vidarabine, Acyclovir, Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more

Conditions: HIV Infections
Interventions: Raltegravir; valproic acid; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Lima, Ohio

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Cidofovir, Probenecid; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Surgical Site Infection, Cesarean Section; Complications, Wound, Infection (Following Delivery), Postpartum Complication
Interventions: Steri3X, Control; Device · Other
Lead sponsor: University of Tennessee; Other
Eligibility: 16 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Open GI Surgery
Interventions: No intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gram-Positive Infections
Interventions: IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 24 Months
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 4 more

Conditions: MRSA
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 6 Months to 21 Years
Enrollment: 50 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prosthetic-joint Infection
Interventions: VT-X7 Treatment System; Combination Product
Lead sponsor: Osteal Therapeutics, Inc.; Industry
Eligibility: 22 Years to 84 Years
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Grand Junction, Colorado + 11 more

Conditions: Hepatitis
Interventions: hepatitis B vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Years to 14 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Clostridioides Difficile Infection
Interventions: CRS3123, Active Comparator; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Lancaster, California • Mission Hills, California + 14 more

Conditions: Sinusitis
Interventions: XprESS device and PathAssist confirmation tools; Device
Lead sponsor: Entellus Medical, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • Salem, Oregon • Charleston, South Carolina + 1 more

Conditions: HIV Infections, Pregnancy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Search by objective public record fields.

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

Botswana Tenofovir Oral HIV Prophylaxis Trial

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

Community Acquired Pneumonia in Older Adults

Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

The Use of Steri3X for Prevention of Post-operative Wound Infections in Cesarean Sections

Surgical Site Infections and the Microbiome: Understanding the Pathogenesis of Surgical Site Infections

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Surveillance of Community-Associated MRSA

Rapid HIV Tests for Women Late in Pregnancy and During Labor

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty

Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

Sinus Balloon Dilation in Pediatric Patients

A Study of HIV Levels During Pregnancy and After Childbirth